Loading…
Elicio Therapeutics, Inc. is projected to rise to $5.33 by 2027, a +53% move from its current price of $3.48. ELTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.13 | $3.48 | $3.88 | +0.02% |
| Jul 14 | $2.99 | $3.48 | $4.05 | +0.03% |
| Jul 15 | $2.89 | $3.48 | $4.19 | +0.05% |
| Jul 16 | $2.81 | $3.48 | $4.32 | +0.06% |
| Jul 17 | $2.74 | $3.48 | $4.43 | +0.08% |
| Jul 18 | $2.68 | $3.48 | $4.53 | +0.09% |
| Jul 19 | $2.62 | $3.48 | $4.63 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.62 | $3.48 | $4.63 | +0.11% |
| Week 2 | $2.33 | $3.49 | $5.21 | +0.22% |
| Week 3 | $2.13 | $3.49 | $5.71 | +0.33% |
| Week 4 | $1.98 | $3.50 | $6.17 | +0.43% |
| Week 5 | $1.85 | $3.50 | $6.60 | +0.54% |
| Week 6 | $1.75 | $3.50 | $7.03 | +0.65% |
| Week 7 | $1.65 | $3.51 | $7.44 | +0.76% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company that develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted AMP peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant BRAF-driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics is headquartered in Boston, Massachusetts.
The company operates in the Healthcare category.
Elicio Therapeutics, Inc. (ELTX) is categorized in Healthcare and trades with a current price of $3.49, a market cap of $66.61M, and a rank of 4431.
The near-term 30-day trading range spans $1.64 to $7.41, reflecting notable intraday volatility. The price outlook over the forecast horizon is bullish, with the average forecast rising from $3.49 in 2026 to higher levels in subsequent years. By 2030, the average is projected at $5.91 and by 2050 at $29.33, with a possible max of $67.46 in 2050.
Across the forecast, implied ROIs rise from 0% in 2026 to 56.7% in 2027, then progressively higher—reaching 69.4% in 2030 and extending to 740.4% by 2050. The 2026 sentiment is NEUTRAL, turning BULLISH in later years as the average price climbs.
A major floor 20.7% below — a decisive break under it would weaken the trend.
The nearest floor, 20.7% below — buyers have tended to step in here.
The nearest ceiling, 326.7% above — a clean break opens room to run.
A major ceiling 449.4% above — clearing it would confirm fresh momentum.
Key ELTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ELTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.31 | Buy | $3.48 | Buy |
| MA 10 | $3.68 | Sell | $3.84 | Sell |
| MA 20 | $4.85 | Sell | $5.14 | Sell |
| MA 50 | $8.64 | Sell | $7.56 | Sell |
| MA 100 | $9.92 | Sell | $8.75 | Sell |
| MA 200 | $9.41 | Sell | $9.05 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.89 | Neutral |
| Stoch RSI (14) | 62.34 | Neutral |
| CCI (20) | -47.12 | Neutral |
| Williams %R (14) | -70.94 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | -15.33 | Sell |
| Bollinger %B (20,2) | 0.39 | Neutral |
| Stochastic %K (14) | 29.06 | Neutral |
| TRIX (15) | -3.21 | Sell |
| Awesome (5,34) | -4.49 | Sell |
| Ultimate (7,14,28) | 44.15 | Neutral |
| Momentum (10) | -0.27 | Sell |
| Aroon Osc (25) | -8.00 | Sell |
| Hull MA (9) | 3.19 | Buy |
| ADX (14) | 28.68 | Sell |
| ATR (14) | 0.72 | Info |
The near-term technical picture is NEUTRAL, with RSI(14) at 40. The stock’s moving averages show SMA50 at $8.95 and SMA200 at $9.49. These values provide context for momentum relative to the price level.
Key support is at $2.76 and resistance at $14.85, framing an upside potential if the stock advances. The 30-day trading range runs from a low of $1.64 to a high of $7.41. The stock exhibits elevated volatility, with annualized volatility at 200%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.76 | $3.48 | $4.82 | 0% | Neutral | |
| $3.87 | $5.33 | $7.95 | +53% | Bullish | |
| $3.39 | $4.96 | $7.88 | +43% | Bullish | |
| $3.39 | $5.23 | $8.72 | +50% | Bullish | |
| $3.37 | $5.45 | $9.46 | +57% | Bullish | |
| $2.98 | $5.04 | $9.06 | +45% | Bullish | |
| $4.10 | $7.24 | $13.40 | +108% | Bullish | |
| $4.89 | $8.98 | $17.09 | +158% | Bullish | |
| $4.91 | $9.39 | $18.33 | +170% | Bullish | |
| $5.39 | $10.71 | $21.39 | +208% | Bullish | |
| $7.65 | $17.01 | $37.33 | +389% | Bullish | |
| $10.05 | $22.33 | $51.35 | +542% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.76 | $3.48 | $4.12 | +0.00% |
| August 2026 | $2.75 | $3.34 | $4.21 | -4.15% |
| September 2026 | $2.87 | $3.53 | $4.55 | +5.81% |
| October 2026 | $2.81 | $3.50 | $4.58 | -0.91% |
| November 2026 | $2.67 | $3.36 | $4.46 | -4.05% |
| December 2026 | $2.82 | $3.58 | $4.82 | +6.59% |
Click any year to see its month-by-month ELTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Elicio Therapeutics, Inc.'s 2026 outlook centres on $3.48, within a $2.76 to $4.82 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ELTX could reach as high as $7.95, with a base case around $5.33 and support toward $3.87 — roughly +53% from $3.48. Buyers look set to stay in control over this stretch.
Expect ELTX to range from $3.39 to $7.88 through 2028. The $4.96 average target implies a +43% move from current prices. That is -7% versus the projected 2027 average. Momentum favours further upside here.
The ELTX price prediction for 2029 points to an average of $5.23 (low $3.39, high $8.72) — a potential gain of +50% on today's $3.48. Buyers look set to stay in control over this stretch.
In 2030, ELTX is projected to trade between $3.37 and $9.46, averaging $5.45 — a potential gain of +57% from today's $3.48. That is up +4% on the projected 2029 average. Momentum favours further upside here.
Elicio Therapeutics, Inc.'s 2031 outlook centres on $5.04, within a $2.98 to $9.06 range. That is -8% versus the projected 2030 average. That marks a +45% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ELTX could reach as high as $13.40, with a base case around $7.24 and support toward $4.10 — roughly +108% from $3.48. Momentum favours further upside here.
Expect ELTX to range from $4.89 to $17.09 through 2033. The $8.98 average target implies a +158% move from current prices. That is up +24% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ELTX price prediction for 2034 points to an average of $9.39 (low $4.91, high $18.33) — a potential gain of +170% on today's $3.48. Momentum favours further upside here.
In 2035, ELTX is projected to trade between $5.39 and $21.39, averaging $10.71 — a potential gain of +208% from today's $3.48. That is up +14% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Elicio Therapeutics, Inc.'s 2040 outlook centres on $17.01, within a $7.65 to $37.33 range. That is up +59% on the projected 2035 average. That marks a +389% change versus current levels. Momentum favours further upside here.
By 2050, ELTX could reach as high as $51.35, with a base case around $22.33 and support toward $10.05 — roughly +542% from $3.48. Buyers look set to stay in control over this stretch.
Investing $1,000 in ELTX today (≈ 287.356322 ELTX) could be worth
$6,416.16
+$5,416.16 (+542%) by 2050 · US Dollar
Based on the average projected ELTX price of $22.33 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ELTXwould be worth at today's price.
$1,000 invested in ELTX on Jul 10, 2025 (≈ 120.918978 ELTX) would be worth
$420.8
-$579.2 (-57.9%) today · 0.42× · US Dollar
Based on a ELTX entry price of $8.27 vs. today's $3.48.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.22 | $1,080.75 | +8.1% |
| 1 month ago | $14.3 | $243.36 | -75.7% |
| 3 months ago | $10.15 | $342.86 | -65.7% |
| 6 months ago | $7.74 | $449.61 | -55.0% |
| 1 year ago | $8.27 | $420.8 | -57.9% |
| All time (5.0y) ago | $111 | $31.35 | -96.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ELTX forecast.
Our base-case forecast reaches $7.00 around 2032.
Implied market cap at $7.00: $183.85M
The multi-year forecast outlines a bullish trajectory across the horizon. The average price is projected to rise from $3.49 in 2026 to $5.91 in 2030 and to $29.33 by 2050, while the maximum forecast price climbs to $10.26 in 2030, $46.29 in 2040, and $67.46 in 2050. The corresponding ROIs move from 0% in 2026 to 69.4% in 2030, 504.2% by 2040, and 740.4% by 2050.
The year-by-year freshness includes 2027 at an average of $5.47, 2028 at $5.13, 2029 at $5.57, 2031 at $5.63, 2032 at $8.54, 2033 at $10.50, 2034 at $10.92, 2035 at $12.70, 2040 at $21.09, and 2050 at $29.33. The forecast signals bullish sentiment across most of the period, with strong upside in the later years.
Risks include the high level of volatility shown (200% annualized), and these are estimates rather than guarantees. Investors should consider the speculative nature of these projections and the possibility of outcomes diverging from the forecast.
Tap a question to reveal the answer.
Avg $5.91; Min $3.65; Max $10.26; ROI 69.4%.
Forecasts show a bullish trajectory in multiple years, with an average price of $5.91 by 2030 and a max of $10.26, yielding an ROI of 69.4% in 2030. These are estimates and not guarantees.
The forecast max is $46.29 by 2040 and $67.46 by 2050, so a $50 level would be within the forecast by 2050.
Low $1.64, High $7.41.
Elicio Therapeutics, Inc. Community Discussion
0Share your Elicio Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.